FDA Approves ANDA for Tofacitinib Citrate by MSN
The FDA has approved the ANDA217299 application for Tofacitinib Citrate submitted by MSN.
Published: June 22, 2026
Updated: June 22, 2026
Author: Humanexa Intelligence
Therapeutic area: Immunology / JAK Inhibitor
Asset: Tofacitinib
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Tofacitinib
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of a generic version of Tofacitinib Citrate by MSN introduces significant competition in the immunology market. Pharma companies must reassess their pricing strategies and market positioning to maintain their competitive edge against this new entrant.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market uptake of the generic and any potential pricing adjustments from competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.